Filing Flows

Filing Flows › 8-K events › NovoCure

NovoCure: regulation fd disclosure

Form 8-K filed Nov 9, 2026 · items 7.01

FDA decisionsNovocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer

What the filing says

Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer

Read the filing on SEC EDGAR →

NovoCure at a glance

Latest quarterQ3 2026
Revenue$193.4M
Revenue Y/Y+16%
Operating margin-3.2%
IndustrySurgical & Medical Instruments & Apparatus

NovoCure, Q3 2026: revenue $193M (+16% year over year), operating margin -3.2%. The chart follows the revenue to costs, profit and cash.

NovoCure: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.